載入中
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
前收盤價
US$2.45
−US$0.03 · -1.21%
盤中時間採用ET。市場資料可能有所延遲。
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
日內區間
目前US$2.45
52週區間
目前US$2.45
盤中時間採用ET。市場資料可能有所延遲。
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
日內區間
目前US$2.45
52週區間
目前US$2.45
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 119.9萬 USD | 239.2萬 USD | 70.9萬 USD | 122.2萬 USD | 130.6萬 USD |
| 銷貨成本 | 39.6萬 USD | 50.8萬 USD | 48.8萬 USD | 72.5萬 USD | 71.6萬 USD |
| 毛利 | 80.3萬 USD | 188.4萬 USD | 22.1萬 USD | 49.7萬 USD | 59萬 USD |
| 研究與開發 | 1204.1萬 USD | 813.7萬 USD | 906.6萬 USD | 937萬 USD | 709.2萬 USD |
| 銷售、一般及管理費用 | 1204.9萬 USD | 1026.9萬 USD | 1218.4萬 USD | 917萬 USD | 1095.4萬 USD |
| 營業費用 | 2409萬 USD | 1840.6萬 USD | 2125萬 USD | 1854萬 USD | 1804.6萬 USD |
| 利息支出 | — | — | — | — | 4000 USD |
| 折舊和攤銷 | 122.6萬 USD | 95.8萬 USD | 94.6萬 USD | 89.3萬 USD | 91.4萬 USD |
| 營業利益 | −2328.7萬 USD | −1652.2萬 USD | −2102.9萬 USD | −1804.3萬 USD | −1745.6萬 USD |
| 淨利 | −2270.4萬 USD | −1597.3萬 USD | −2141.3萬 USD | −1883.5萬 USD | −1704.5萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
